Bio-Techne Corporation (TECH)
Healthcare · NMS
Price as at 1 Oct 2026, 02:26 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Bio-Techne Corporation trades at $72.47, which is 60% above the $28.64 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 53 out of 100, which is a moat, but not a deep one. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 102.3 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
TECH dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | $0.240 | 3 |
| 2025 | $0.320 | 4 |
| 2024 | $0.320 | 4 |
| 2023 | $0.320 | 4 |
| 2022 | $0.320 | 4 |
| 2021 | $0.320 | 4 |
| 2020 | $0.320 | 4 |
| 2019 | $0.320 | 4 |
| 2018 | $0.320 | 4 |
| 2017 | $0.320 | 4 |
| 2016 | $0.320 | 4 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
TECH earnings and analyst estimates
Recommendation mix, 15 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
TECH passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
20 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Ruane Cunniff, Ruane, Cunniff & Goldfarb L.P.$236.60M · 3.7% of book
- Mairs & Power, MAIRS & POWER INC$190.80M · 1.8% of book
- Capital Research Global, Capital Research Global Investors$185.24M · 0.0% of book
- Lee Ainslie, MAVERICK CAPITAL LTD$108.49M · 1.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$69.88M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in TECH
We hold 13 disclosed trades in TECH by members of Congress and executive-branch officials. The latest 5:
- April McClain Delaney · HouseSell · $1,001 - $15,000 · traded 8 Apr 2026 · disclosed 6 May 2026
- April McClain Delaney · HouseSell · $1,001 - $15,000 · traded 26 Mar 2026 · disclosed 6 Apr 2026
- April McClain Delaney · HouseSell · $1,001 - $15,000 · traded 24 Feb 2026 · disclosed 10 Mar 2026
- April McClain Delaney · HouseSell · $1,001 - $15,000 · traded 28 Jan 2026 · disclosed 2 Feb 2026
- April McClain Delaney · HouseBuy · $1,001 - $15,000 · traded 5 Dec 2025 · disclosed 5 Jan 2026
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
TECH peers
The largest companies in the same industry (Biotechnology), then in the same sector.
- CSLLY CSL Limited
- RVMD Revolution Medicines, Inc.
- CMXHF CSL Limited
- ALNY Alnylam Pharmaceuticals, Inc.
- RPRX Royalty Pharma plc
- INCY Incyte Corporation
- INSM Insmed Incorporated
- GNMSF Genmab A/S
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Bio-Techne Corporation (TECH) undervalued?
Against our fair value estimate of $28.64, TECH at $72.47 is 60% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own TECH?
20 of the institutions we track reported a position in TECH in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is TECH's P/E ratio?
TECH trades at 102.3 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Does Bio-Techne Corporation (TECH) pay a dividend?
Yes. Bio-Techne Corporation yields 0.45% at the current share price. It has paid $0.320 per share over the trailing twelve months. It has paid a dividend in each of the last 18 complete calendar years. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
Where does SteadyShares get its TECH data?
Fundamentals for TECH come from company filings and exchange data, as listed on NMS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 02:26 UTC and is delayed. Our data quality score for this company is 100/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for TECH, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.